|
Addex Pharmaceuticals utilizes its unique proprietary platform technologies to discover and develop allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. The Addex pipeline demonstrates the productivity and broad potential of this unparalleled platform. The most advanced product, ADX48621 mGluR5 negative allosteric modulator (NAM), has completed early clinical testing and is scheduled to start mid-stage clinical testing in the fourth quarter of 2010 for treatment of Parkinson's disease levodopa induced dyskinesia.
selected press releases
|
our allosteric modulator discovery laboratories in Geneva media and other exposure
|